Wednesday, July 8, 2026

pharma · Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors · Atopic Dermatitis · HOTH

Hoth Therapeutics

HotHouse Therapeutics is a pharma organization headquartered in Norwich, GB. It trades on NYSE under ticker HOTH. Primary therapeutic focus areas include Skin Toxicities Associated with Epidermal Growth Factor Receptor I

Norwich, GB HQ
12 Employees
Public company Type
HOTH · NYSE Ticker
Company details
Status
Public
HQ
Norwich, GB
Employees
12
Programs
3
Drugs
4
Patents
1
Clinical program

HT-001 2% Topical Gel

Phase 2 · small molecule · Acneiform Eruption Due to Chemical

HT-001 2% Topical Gel for Acneiform Eruption Due to Chemical is a Phase 2 program (small_molecule) at Hoth Therapeutics with 1 ClinicalTrials.gov record(s).

← All Hoth Therapeutics projects Phase 2 small molecule active

Internal code CLEER-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoth Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Acneiform Eruption Due to Chemical
Status
active
Trials
1

Clinical trials